The North America overactive bladder treatment market is expected to grow from US$ 1,682.29 million in 2022 to US$ 2,059.43 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.
Increase in Prevalence of Urinary Incontinence Drives North America Overactive Bladder Treatment Market
Urinary incontinence is the loss of bladder control caused due to the improper functioning of the muscles and nerves that control the passage of urine through the bladder. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. As per the Office on Women's Health, a division of the US Department of Health and Human Services, the prevalence of incontinence in women is twice as in men, and aging, pregnancy, childbirth, and menopause can be the key factors leading to this condition in women. A few other factors affecting the function of muscles and nerves include overweight, constipation, or pelvic surgeries. As stated by the North American Menopause Society (NAMS), in the US, the prevalence of urinary incontinence was 17.1% among women aged 20 years or more and 38% in women aged 60 years and older in 2021. Urinary incontinence can affect women at any age; however, it is more common in older women due to hormonal changes during menopause. Thus, the surge in urinary related diseases is directly driving the North America overactive bladder treatment market .North America Overactive Bladder Treatment Market Overview
The North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the overactive bladder treatment market in 2021, owing to the increase in the geriatric population and prevalence of overactive diseases and Parkinson’s Disease. According to Parkinson’s Foundation, ~1 million people in the US are suffering from Parkinson’s Disease, and it is likely to reach 1.2 million by 2030. Although overactive bladder can occur at any age, it is quite prevalent in the population aged above 60 years. As per the Administration for Community Living, 16% of the US population was aged 65 and above in 2019, and it is expected to reach ~21.6% by 2040. The Population Reference Bureau (PRB) stated that the number of Americans aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. According to Cleveland Clinic Organization, ~33 million adults in the US are affected by an overactive bladder. Further, an article by John Wiley & Sons, Inc. stated that ~17% of the US population suffers from this condition. Thus, the demand for overactive bladder treatment is increasing across the region.North America Overactive Bladder Treatment Market Segmentation
The North America overactive bladder treatment market is segmented based on pharmacotherapy, disease type, and country.- Based on pharmacotherapy, the North America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.
- Based on disease type, the North America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.
- Based on country, the North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Overactive Bladder Treatment Market- By Pharmacotherapy
1.3.2 North America Overactive Bladder Treatment Market- By Disease Type
1.3.3 North America Overactive Bladder Treatment Market - By Country
2. North America Overactive Bladder Treatment Market Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Overactive Bladder Treatment Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert Opinion
5. North America Overactive Bladder Treatment Market Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Urinary Incontinence
5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis
6. North America Overactive Bladder Treatment Market - North America Analysis
6.1 North America Overactive Bladder Treatment Market Revenue Forecast and Analysis
7. North America Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy
7.1 Overview
7.2 North America Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
7.3.1 Overview
7.3.2 Mirabegron: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
7.4.1 Overview
7.4.2 Botox: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
7.5.1 Overview
7.5.2 Neurostimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.3 Transcutaneous Sacral Nerve Stimulation
7.5.3.1 Overview
7.5.3.2 Transcutaneous Sacral Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.4 Transcutaneous Tibial Nerve Stimulation
7.5.4.1 Overview
7.5.4.2 Transcutaneous Tibial Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
7.5.5.1 Overview
7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.6 Others
7.5.6.1 Overview
7.5.6.2 Others: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
7.6.1 Overview
7.6.2 Anticholinergics: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.3 Solifenacin
7.6.3.1 Overview
7.6.3.2 Solifenacin: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.4 Oxybutynin
7.6.4.1 Overview
7.6.4.2 Oxybutynin: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.5 Fesoterodine
7.6.5.1 Overview
7.6.5.2 Fesoterodine: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.6 Darifenacin
7.6.6.1 Overview
7.6.6.2 Darifenacin: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.7 Tolterodine
7.6.7.1 Overview
7.6.7.2 Tolterodine: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.8 Trospium
7.6.8.1 Overview
7.6.8.2 Trospium: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.9 Other Anticholinergics
7.6.9.1 Overview
7.6.9.2 Other Anticholinergics: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
7.7.1 Overview
7.7.2 Intravesical Instillation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8. North America Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type
8.1 Overview
8.2 North America Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
8.3.1 Overview
8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
8.4.1 Overview
8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis
9.1 Overview
9.1.2 North America: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
9.1.2.1 US: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.1 US: Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.2 US: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.2.1 US: Overactive Bladder Treatment Market, by Anticholinergics- Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.2.2 US: Overactive Bladder Treatment Market, by Neurostimulation- Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.3 US: Overactive Bladder Treatment Market, by Disease Type- Revenue and Forecast to 2028 (US$ Million)
9.1.2.2 Canada: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.1 Canada: Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.2 Canada: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.2.1 Canada: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.2.2 Canada: Overactive Bladder Treatment Market, by Neurostimulation- Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.3 Canada: Overactive Bladder Treatment Market, by Disease Type- Revenue and Forecast to 2028 (US$ Million)
9.1.2.3 Mexico: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.1 Mexico: Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.2 Mexico: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.2.1 Mexico: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.2.2 Mexico: Overactive Bladder Treatment Market, by Neurostimulation- Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.3 Mexico: Overactive Bladder Treatment Market, by Disease Type- Revenue and Forecast to 2028 (US$ Million)
10. Overactive Bladder Treatment Market- Industry Landscape
10.1 Overview
10.2 Organic Developments
10.2.1 Overview
11. Company Profiles
11.1 Alembic Pharmaceuticals Limited
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Astellas Pharma Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 AbbVie Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Teva Pharmaceutical Industries Ltd
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Endo Pharmaceuticals Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co. Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Medtronic Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Colorado Urology Associates, PLLC
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Axonics Modulation Technologies, Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Pfizer Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
Table 1. US: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 2. US: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 4. US: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 5. Canada: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 10. Mexico: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 11. Mexico: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. Organic Developments Done by Companies
Table 14. Glossary of Terms
Figure 1. North America Overactive Bladder Treatment Market Segmentation
Figure 2. North America Overactive Bladder Treatment Market Segmentation, By Country
Figure 3. North America Overactive Bladder Treatment Market Overview
Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in North America Overactive Bladder Treatment market
Figure 5. US Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. North America: PEST Analysis
Figure 8. North America Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
Figure 9. North America Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2019- 2028
Figure 10. North America Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
Figure 11. Mirabegron: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Botox: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Neurostimulation: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Transcutaneous Sacral Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Transcutaneous Tibial Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
Figure 16. Percutaneous Posterior Tibial Nerve: North America Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
Figure 17. Others: North America Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
Figure 18. Anticholinergics: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Solifenacin: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Oxybutynin: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Fesoterodine: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Darifenacin: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Tolterodine: North America Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Trospium: North America Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Other Anticholinergics: North America Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Intravesical Instillation: North America Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. North America Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
Figure 28. Idiopathic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Neurogenic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 30. North America: Overactive Bladder Treatment Market Revenue Overview, By Key Country - Revenue (2021) (US$ Million)
Figure 31. North America: Overactive Bladder Treatment Market, By Country, 2021 & 2028 (%)
Figure 32. US: Overactive Bladder Treatment Market Revenue and Forecast To 2028 (US$ Million)
Figure 33. Canada: Overactive Bladder Treatment Market Revenue and Forecast To 2028 (US$ Million)
Figure 34. Mexico: Overactive Bladder Treatment Market Revenue and Forecast To 2028 (US$ Million)
Companies Mentioned
- AbbVie Inc
- Alembic Pharmaceuticals Limited
- Astellas Pharma Inc
- Axonics Modulation Technologies, Inc
- Colorado Urology Associates, PLLC
- Endo Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- Medtronic Plc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | January 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1682.29 Million |
| Forecasted Market Value ( USD | $ 2059.43 Million |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | North America |
| No. of Companies Mentioned | 10 |
